MRI measures of corpus callosum iron and myelin in early Huntington's disease

Human Brain Mapping

Volumn 35, Issue 7, 2014, Pages 3143-3151

  Di Paola, M ^a,b   Phillips, O R ^a   Sanchez Castaneda, C ^a,c   Di Pardo, A ^d   Maglione, V ^d   Caltagirone, C ^a,e   Sabatini, U ^a   Squitieri, F ^d  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

^d IRCCS NEUROMED   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Corpus callosum; Diffusion tensor imaging; Huntington's disease; Iron; Magnetic resonance based relaxometry; White matter

Indexed keywords

IRON; MYELIN;

ADULT; ARTICLE; BRAIN MAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS CALLOSUM; DIFFUSION TENSOR IMAGING; DISEASE MARKER; ECHO PLANAR IMAGING; FEMALE; HUMAN; HUNTINGTON CHOREA; IRON METABOLISM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; VOXEL BASED MORPHOMETRY; METABOLISM; MIDDLE AGED; MYELIN SHEATH; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; THREE DIMENSIONAL IMAGING;

ADULT; CORPUS CALLOSUM; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGING, THREE-DIMENSIONAL; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYELIN SHEATH; PSYCHIATRIC STATUS RATING SCALES;

EID: 84902159155     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.22391     Document Type: Article

References (39)

1. Ashburner J, Friston KJ (2000): Voxel-based morphometry-The methods. Neuroimage 11(6 Part 1):805-821.
2. Bartzokis G (2005): Brain myelination in prevalent neuropsychiatric developmental disorders: Primary and comorbid addiction. Adolesc Psychiatry 29:55-96.
3. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J (1999): Increased basal ganglia iron levels in Huntington disease. Arch Neurol 56:569-574.
4. Bartzokis G, Lu PH, Tishler TA, Fong SM, Oluwadara B, Finn JP, Huang D, Bordelon Y, Mintz J, Perlman S (2007): Myelin breakdown and iron changes in Huntington's disease: Pathogenesis and treatment implications. Neurochem Res 32:1655-1664.
5. Bartzokis G, Lu PH, Heydari P, Couvrette A, Lee GJ, Kalashyan G, Freeman F, Grinstead JW, Villablanca P, Finn JP, Mintz J, Alger JR, Altshuler LL (2012): Multimodal magnetic resonance imaging assessment of white matter aging trajectories over the lifespan of healthy individuals. Biol Psychiatry 72:1026-1034.
6. Bartzokis G, Tishler TA (2000): MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand) 46:821-833.
7. Beal MF (1996): Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol 6:661-666.
8. Cherubini A, Peran P, Caltagirone C, Sabatini U, Spalletta G (2009): Aging of subcortical nuclei: Microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 48:29-36.
9. Connor JR, Menzies SL, St Martin SM, Mufson EJ (1990): Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res 27:595-611.
10. Deichmann R, Schwarzbauer C, Turner R (2004): Optimisation of the 3D MDEFT sequence for anatomical brain imaging: Technical implications at 1.5 and 3 T. Neuroimage 21:757-767.
11. Di Paola M, Luders E, Cherubini A, Sanchez-Castaneda C, Thompson PM, Toga AW, Caltagirone C, Orobello S, Elifani F, Squitieri F, Sabatini U (2012): Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease. Cereb Cortex 22:2858-2866.
12. Folstein MF, Folstein SE, McHugh PR (1975): "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
13. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001): A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14(1 Part 1):21-36.
14. He X, Yablonskiy DA (2009): Biophysical mechanisms of phase contrast in gradient echo MRI. Proc Natl Acad Sci USA 106:13558-13563.
15. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, MacDonald ME (2000): Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 9:2789-2797.
16. Hobbs NZ, Henley SM, Ridgway GR, Wild EJ, Barker RA, Scahill RI, Barnes J, Fox NC, Tabrizi SJ (2010): The progression of regional atrophy in premanifest and early Huntington's disease: A longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 81:756-763.
17. Huntington, Study, Group. (1996): Unified Huntington's Disease Rating Scale: Reliability and consistency. Mov Disord 11:136-142.
18. Koeppen AH (1995): The history of iron in the brain. J Neurol Sci 134:1-9.
19. LeVine SM, Macklin WB (1990): Iron-enriched oligodendrocytes: A reexamination of their spatial distribution. J Neurosci Res 26:508-512.
20. Li W, Wu B, Avram AV, Liu C (2012): Magnetic susceptibility anisotropy of human brain in vivo and its molecular underpinnings. Neuroimage 59:2088-2097.
21. Moos T, Morgan EH (2004): The metabolism of neuronal iron and its pathogenic role in neurological disease: Review. Ann NY Acad Sci 1012:14-26.
22. Nguyen T, Hamby A, Massa SM (2005): Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102:11840-11845.
23. Nichols TE, Holmes AP (2002): Nonparametric permutation tests for functional neuroimaging: A primer with examples. Hum Brain Mapp 15:1-25.
24. Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS (2010): Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 40:544-554.
25. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I (2001): Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57:658-662.
26. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997): CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41:689-692.
27. Peran P, Cherubini A, Luccichenti G, Hagberg G, Demonet JF, Rascol O, Celsis P, Caltagirone C, Spalletta G, Sabatini U (2009): Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp 30:2667-2675.
28. Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, Fischl B, Pappu V, Onorato C, Cha JH, Salat DH, Hersch SM (2010): Altered white matter microstructure in the corpus callosum in Huntington's disease: Implications for cortical "disconnection". Neuroimage 49:2995-3004.
29. Salvador GA, Uranga RM, Giusto NM (2011): Iron and mechanisms of neurotoxicity. Int J Alzheimers Dis 720658.
30. Sánchez-Castañeda C, Cherubini A, Elifani F, Péran P, Orobello S, Capelli G, Sabatini U, Squitieri F (2013): Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp 34:1625-1635.
31. Schulz K, Vulpe CD, Harris LZ, David S (2011): Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J Neurosci 31:13301-13311.
32. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews PM, Behrens TE (2006): Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. Neuroimage 31:1487-1505.
33. Specht K, Minnerop M, Muller-Hubenthal J, Klockgether T (2005): Voxel-based analysis of multiple-system atrophy of cerebellar type: Complementary results by combining voxel-based morphometry and voxel-based relaxometry. Neuroimage 25:287-293.
34. Thomas M, Jankovic J (2004): Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol 17:437-442.
35. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR (2009): Oligodendrocytes and myelination: The role of iron. Glia 57:467-478.
36. Vonsattel JP, Keller C, Del Pilar Amaya M (2008): Neuropathology of Huntington's disease. In: Duyckaerts C, Litvan I, editors. Handbook of Clinical Neurology Amsterdam: Elsevier. pp 599-618.
37. Yablonskiy DA, Haacke EM (1994): Theory of NMR signal behavior in magnetically inhomogeneous tissues: The static dephasing regime. Magn Reson Med 32:749-763.
38. Youdim MB, Stephenson G, Ben Shachar D (2004): Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: A lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann NY Acad Sci 1012:306-325.
39. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004): Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863-873.